Takeda Pharmaceutical Q1 Core EPS ¥176 Up From ¥150; Sales ¥1.208T Beat ¥1.089T Estimate
Portfolio Pulse from Benzinga Newsdesk
Takeda Pharmaceutical reported a strong Q1 with Core EPS of ¥176, up from ¥150, and sales of ¥1.208 trillion, beating the estimate of ¥1.089 trillion.
July 31, 2024 | 6:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Takeda Pharmaceutical's Q1 results show significant growth with Core EPS of ¥176, up from ¥150, and sales of ¥1.208 trillion, surpassing the estimate of ¥1.089 trillion.
The strong Q1 performance with higher-than-expected Core EPS and sales indicates robust business growth, likely leading to a positive short-term impact on Takeda's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100